Skip to main content

$0.007 0.001 (16.67%)

High

$0.01

Low

$0.01

Trades

19

Turnover

$1,131

Volume

188,484
30 June 2023 at 4:10pm
Register to track ATH and receive email alerts.
Subject
ATH Ann: Change in substantial holding

ATH Ann: ATH434 Phase 2 clinical launched in Europe

ATH Ann: Extension to regain NASDAQ minimum bid price compliance

ATH Ann: Change in substantial holding

ATH Ann: Appendix 4C and Quarterly Cash Flow Report

ATH Ann: Change in substantial holding

ATH Ann: First Patient dosed in ATH434 Phase 2 Clinical Trial

ATH Ann: Alterity receives a $4.1 million R&D Tax Refund

ATH Ann: Notification of cessation of securities - ATH

ATH Ann: Regulatory Approval to Proceed with Phase 2 Trial in Italy

ATH Ann: Alterity to Present at Life Sciences Investor Forum

ATH Ann: Alterity to present at GCFF Virtual Conference 2022

ATH Ann: Alterity Launches ATH434 Phase 2 Clinical Trial

ATH Ann: Alterity to Participate in the Benchmark Company Conference

ATH Ann: Change in substantial holding

ATH Ann: Appendix 4C and Quarterly Cash Flow Report

ATH Ann: UK Regulatory Authorisation to Proceed with Phase 2 Trial

ATH Ann: Presentation of bioMUSE Data at the AAN Annual Meeting

ATH Ann: Change in substantial holding

ATH Ann: Change in substantial holding

ATH Ann: Alterity to participate in Sachs Neuroscience Conference

ATH Ann: Investor Presentation

ATH Ann: Alterity to Present at the 34th Annual Roth Conference

ATH Ann: NASDAQ Non-Compliance Notice Received

ATH Ann: Half Yearly Report and Accounts

ATH Ann: New publication shows ATH434 rescues neurons in MSA model

ATH Ann: Appendix 4C and Quarterly Cash Flow Report

ATH Ann: Change in substantial holding

ATH Ann: Response to ASX Query

ATH Ann: Change in substantial holding

ATH Ann: New US Patent for Compounds to Treat Neurodegeneration

ATH Ann: Alterity to present at H.C. Wainwright Conference

ATH Ann: Final Director's Interest Notice x 2

ATH Ann: Notification of cessation of securities - ATH

ATH Ann: Alterity announces resignation of Non-Executive Directors

ATH Ann: Change in substantial holding

ATH Ann: Notification of cessation of securities - ATH

ATH Ann: First Regulatory Authorization to Proceed with Phase 2 Trial

ATH Ann: Notification regarding unquoted securities - ATH

ATH Ann: Change in substantial holding

ATH Ann: Change in substantial holding

ATH Ann: Alterity to present at upcoming investor conferences

ATH Ann: Results of Annual General Meeting

ATH Ann: ATH Annual General Meeting Presentation

ATH Ann: Chairman's Address 2021 Annual General Meeting

ATH Ann: Alterity presents at American Autonomic Society Meeting

ATH Ann: New Data Advance ATH434 as Neurodegeneration treatment

ATH Ann: Change in substantial holding

ATH Ann: Appendix 4C and Quarterly Cash Flow Report

ATH Ann: Expanded ATH434 Phase 2 Clinical Development Program

Register to track ATH and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX